<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02675426</url>
  </required_header>
  <id_info>
    <org_study_id>M13-549</org_study_id>
    <secondary_id>2015-003332-13</secondary_id>
    <nct_id>NCT02675426</nct_id>
  </id_info>
  <brief_title>A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone</brief_title>
  <acronym>SELECT-NEXT</acronym>
  <official_title>A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to compare the efficacy, safety, and tolerability of
      upadacitinib 30 mg once daily (QD) and 15 mg QD versus placebo for the treatment of signs and
      symptoms of adults with moderately to severely active rheumatoid arthritis who were on a
      stable dose of csDMARDs and had an inadequate response to csDMARDs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 3 multicenter study included two periods. Period 1 was a 12-week, randomized,
      double-blind, parallel-group, placebo-controlled period designed to compare the safety and
      efficacy of upadacitinib 30 mg once daily and 15 mg once daily versus placebo for the
      treatment of signs and symptoms of adults with moderately to severely active rheumatoid
      arthritis (RA) who were on a stable dose of csDMARDs and had an inadequate response to
      csDMARDs.

      Period 2 is a blinded long-term (up to 5 years) extension period to evaluate the long-term
      safety, tolerability, and efficacy of upadacitinib 30 mg once daily and 15 mg daily in
      participants who had completed Period 1 that is currently ongoing.

      Participants were to be randomized in a 2:2:1:1 ratio using interactive response technology
      (IRT) to receive double-blind study drug in one of the following treatment groups:

        -  Group 1: Upadacitinib 30 mg QD in Period 1 → Upadacitinib 30 mg QD in Period 2

        -  Group 2: Upadacitinib 15 mg QD in Period 1 → Upadacitinib 15 mg QD in Period 2

        -  Group 3: Placebo in Period 1 → Upadacitinib 30 mg QD in Period 2

        -  Group 4: Placebo in Period 1 → Upadacitinib 15 mg QD in Period 2

      Randomization was stratified by prior exposure to biological disease-modifying anti-rheumatic
      drug (bDMARD) (yes/no) and geographic region.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 17, 2015</start_date>
  <completion_date type="Anticipated">February 17, 2022</completion_date>
  <primary_completion_date type="Actual">April 21, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12</measure>
    <time_frame>Baseline and week 12</time_frame>
    <description>The primary endpoint for United States (US)/Food and Drug Administration (FDA) regulatory purposes was ACR 20% response (ACR20) at Week 12. Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria:
≥ 20% improvement in 68-tender joint count;
≥ 20% improvement in 66-swollen joint count; and
≥ 20% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Health Assessment Questionnaire - Disability Index (HAQ-DI)
High-sensitivity C-reactive protein (hsCRP).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The primary endpoint for European Union (EU)/European Medicines Agency (EMA) regulatory purposes was low disease activity, based on a Disease Activity Score 28 (DAS28)-CRP score of ≤ 3.2 at week 12.
The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.
A DAS28 score less than or equal to 3.2 indicates low disease activity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in in Disease Activity Score 28 (CRP) at Week 12</measure>
    <time_frame>Baseline and week 12</time_frame>
    <description>The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from baseline in DAS28 (CRP) indicates improvement in disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12</measure>
    <time_frame>Baseline and week 12</time_frame>
    <description>The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability.
A negative change from Baseline in the overall score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health).
The physical component score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from baseline score indicates an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Clinical Remission Based on DAS28 (CRP) at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Clinical remission (CR) based on DAS28 (CRP) is defined as achieving a DAS28 (CRP) of less than 2.6.
DAS28 (CRP) is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Low Disease Activity Based on CDAI at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Low disease activity based on the clinical disease activity index (CDAI) is defined as a CDAI score ≤ 10.
CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Duration of Morning Stiffness at Week 12</measure>
    <time_frame>Baseline and week 12</time_frame>
    <description>Participants were asked to indicate the time it took for them to get as limber as possible after awakening with morning stiffness over the past 7 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F)</measure>
    <time_frame>Baseline and week 12</time_frame>
    <description>The FACIT Fatigue scale is a 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four point Likert scale. The FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12</measure>
    <time_frame>Baseline and week 12</time_frame>
    <description>Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR50 response criteria:
≥ 50% improvement in 68-tender joint count;
≥ 50% improvement in 66-swollen joint count; and
≥ 50% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Health Assessment Questionnaire - Disability Index (HAQ-DI)
High-sensitivity C-reactive protein (hsCRP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12</measure>
    <time_frame>Baseline and week 12</time_frame>
    <description>Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR70 response criteria:
≥ 70% improvement in 68-tender joint count;
≥ 70% improvement in 66-swollen joint count; and
≥ 70% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Health Assessment Questionnaire - Disability Index (HAQ-DI)
High-sensitivity C-reactive protein (hsCRP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1</measure>
    <time_frame>Baseline and week 1</time_frame>
    <description>Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria:
≥ 20% improvement in 68-tender joint count;
≥ 20% improvement in 66-swollen joint count; and
≥ 20% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Health Assessment Questionnaire - Disability Index (HAQ-DI)
High-sensitivity C-reactive protein (hsCRP).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">661</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Upadacitinib 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Participants receive Upadacitinib 15 mg once daily for 12 weeks.
Period 2: Participants will continue on Upadacitinib 15 mg once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Upadacitinib 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Participants receive Upadacitinib 30 mg once daily for 12 weeks.
Period 2: Participants will continue on Upadacitinib 30 mg once daily until participants begin to receive Upadacitinib 15 mg once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and Upadacitinib 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Participants receive Placebo once daily for 12 weeks.
Period 2: Participants will receive Upadacitinib 15 mg once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and Upadacitinib 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Participants receive Placebo once daily for 12 weeks.
Period 2: Participants will receive Upadacitinib 30 mg once daily until participants begin to receive Upadacitinib 15 mg once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet; Oral</description>
    <arm_group_label>Placebo and Upadacitinib 15 mg</arm_group_label>
    <arm_group_label>Placebo and Upadacitinib 30 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Upadacitinib</intervention_name>
    <description>Tablet; Oral</description>
    <arm_group_label>Placebo and Upadacitinib 15 mg</arm_group_label>
    <arm_group_label>Placebo and Upadacitinib 30 mg</arm_group_label>
    <arm_group_label>Upadacitinib 15 mg</arm_group_label>
    <arm_group_label>Upadacitinib 30 mg</arm_group_label>
    <other_name>ABT-494</other_name>
    <other_name>Rinvoq</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult male or female, at least 18 years old.

          -  Diagnosis of Rheumatoid Arthritis (RA) for greater than or equal to 3 months.

          -  Subjects have been receiving conventional synthetic DMARD (csDMARD) therapy for
             greater than or equal to 3 months and on a stable dose for greater than or equal to 4
             weeks prior to the first dose of study drug. The following csDMARDs are allowed:
             Methotrexate (MTX), sulfasalazine, hydroxychloroquine, chloroquine, and leflunomide.

          -  Meets the following minimum disease activity criteria: greater than or equal to 6
             swollen joints (based on 66 joint counts) and greater than or equal to 6 tender joints
             (based on 68 joint counts) at Screening and Baseline Visits.

          -  Subjects with prior exposure to at most one biologic DMARD (bDMARD) may be enrolled
             (up to 20% of study population) if they have documented evidence of intolerance to
             bDMARDs or limited exposure (less than 3 months) and have satisfied required washout
             periods.

        Exclusion Criteria:

          -  Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to
             tofacitinib, baricitinib, and filgotinib).

          -  History of inflammatory joint disease other than RA. History of secondary Sjogren's
             Syndrome is permitted.

          -  Subjects who are considered inadequate responders to bDMARD therapy as determined by
             the Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AZ Arthritis and Rheum Assoc /ID# 148651</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SunValley Arthritis Center, Lt /ID# 140452</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Arthritis and Rheum Researc /ID# 138500</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032-9306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Arthritis and Rheum Researc /ID# 139286</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032-9306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Arthritis &amp; Rheuma Research /ID# 138598</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Research Center, Inc. /ID# 140448</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85053-4061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arizona Cancer Center - North Campus /ID# 140451</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719-1478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covina Arthritis Clinic /ID# 139881</name>
      <address>
        <city>Covina</city>
        <state>California</state>
        <zip>91722</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>T. Joseph Raoof, MD, Inc. /ID# 140964</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Rheum Med Clin /ID# 146082</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Arthritis Ctr Med Grp /ID# 138744</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robin K. Dore MD, Inc /ID# 138688</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inland Rheum Clin Trials Inc. /ID# 138853</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Arthritis Clinic /ID# 139876</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Res of West FL, Inc. /ID# 138854</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ctr Arthritis &amp; Rheumatic Dise /ID# 141696</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medallion Clinical Research Institute, LLC /ID# 140074</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suncoast Clinical Research /ID# 138633</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Research Consultants /ID# 139877</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Center, Inc. /ID# 141363</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Arthritis Res /ID# 138548</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OrthoIllinois /ID# 139695</name>
      <address>
        <city>Rockford</city>
        <state>Illinois</state>
        <zip>61114-4937</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigation Special /ID# 139696</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Springfield Clinic /ID# 138602</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702-3749</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deerbrook Medical Associates /ID# 139694</name>
      <address>
        <city>Vernon Hills</city>
        <state>Illinois</state>
        <zip>60061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Univ School of Med /ID# 140077</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bluegrass Community Research /ID# 138295</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40515</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Four Rivers Clinical Research /ID# 141134</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MMP Women's Health /ID# 141542</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Rheumatology &amp; /ID# 139203</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mansfield Health Center /ID# 141357</name>
      <address>
        <city>Mansfield</city>
        <state>Massachusetts</state>
        <zip>02048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Rheumatology, PC /ID# 140071</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Justus J. Fiechtner, MD, PC /ID# 138697</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physician Res. Collaboration /ID# 138533</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westroads Clinical Research /ID# 138304</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Rheumatology /ID# 138746</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Salisbury /ID# 141023</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington LLC /ID# 140951</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Rheumatic Disease Study Group, Inc. /ID# 138868</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242-4468</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Assoc of NW Ohio /ID# 140953</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Research Oklahoma /ID# 138535</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103-2400</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Ctr Clinical Res /ID# 138741</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Articularis Healthcare Group, Inc d/b/a Low Country Rheumatology /ID# 138689</name>
      <address>
        <city>Summerville</city>
        <state>South Carolina</state>
        <zip>29486-7887</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Arthritis Care, a division of Comprehensive Rheumatology Care PLLC /ID# 141021</name>
      <address>
        <city>Hendersonville</city>
        <state>Tennessee</state>
        <zip>37075-6213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tekton Research, Inc. /ID# 141428</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trinity Universal Res Assoc /ID# 149271</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arth and Osteo Clin Brazo Valley /ID# 147809</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metroplex Clinical Research /ID# 138698</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine /ID# 138682</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-3411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Institute for Clin Res /ID# 138716</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Consultants, P.A. /ID# 141138</name>
      <address>
        <city>Killeen</city>
        <state>Texas</state>
        <zip>76549</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trinity Universal Research Association /ID# 148649</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75024-5283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Management /ID# 139338</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis &amp; Osteoporosis Clinic /ID# 138703</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Washington Arthritis C /ID# 138728</name>
      <address>
        <city>Bothell</city>
        <state>Washington</state>
        <zip>98021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Northwest, PLLC /ID# 138539</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Rheumatology and Immunotherapy Center /ID# 139306</name>
      <address>
        <city>Franklin</city>
        <state>Wisconsin</state>
        <zip>53132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mautalen Salud e Investigacion /ID# 141419</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1128</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inst. Rheumatologic Strusberg /ID# 145648</name>
      <address>
        <city>Cordoba</city>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coffs Clinical Trials /ID# 138747</name>
      <address>
        <city>Coffs Harbour</city>
        <state>New South Wales</state>
        <zip>2450</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimus Clinical Research Pty. /ID# 138769</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emeritus Research /ID# 138773</name>
      <address>
        <city>Camberwell</city>
        <state>Victoria</state>
        <zip>3124</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barwon Rheumatology /ID# 138772</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheuma Zentrum Favoriten GmbH /ID# 138787</name>
      <address>
        <city>Vienna</city>
        <zip>1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilhelminenspital der Stadt Wien /ID# 138788</name>
      <address>
        <city>Wien</city>
        <zip>1160</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhumaconsult SPRL /ID# 138813</name>
      <address>
        <city>Charleroi</city>
        <state>Hainaut</state>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent /ID# 138806</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint Lucas /ID# 141338</name>
      <address>
        <city>Brugge</city>
        <zip>8310</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Centre of the Republic of Srpska /ID# 138819</name>
      <address>
        <city>Banja Luka</city>
        <state>Republika Srpska</state>
        <zip>78000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Centre of the Republic of Srpska /ID# 140372</name>
      <address>
        <city>Banja Luka</city>
        <state>Republika Srpska</state>
        <zip>78000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diag Consult Ctr 17 Sofia EOOD /ID# 141006</name>
      <address>
        <city>Sofia</city>
        <zip>1505</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic Consultative Center /ID# 138882</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manitoba Clinic /ID# 139086</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A IM3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Health /ID# 140431</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe de Recherche en Maladies Osseuses /ID# 138906</name>
      <address>
        <city>Sainte-foy</city>
        <state>Quebec</state>
        <zip>G1V 3M7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Latha Naik /ID# 139089</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7K 3H3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinicki bolnicki centar Rijeka /ID# 138649</name>
      <address>
        <city>Rijeka</city>
        <state>Primorsko-goranska Zupanija</state>
        <zip>51000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinicka bolnica Sveti Duh /ID# 152812</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Kuna-Peric /ID# 140365</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poliklinika Bonifarm /ID# 141415</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L.K.N. Arthrocentrum, s.r.o /ID# 141340</name>
      <address>
        <city>Hlučín</city>
        <state>Moravskoslezsky Kraj</state>
        <zip>748 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologie, s.r.o. /ID# 138899</name>
      <address>
        <city>Brno</city>
        <zip>638 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Artroscan s.r.o. /ID# 138833</name>
      <address>
        <city>Ostrava</city>
        <zip>722 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Slany /ID# 141112</name>
      <address>
        <city>Slany</city>
        <zip>274 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PV-MEDICAL s.r.o. /ID# 138913</name>
      <address>
        <city>Zlin</city>
        <zip>760 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center of Clinical and Basic Research /ID# 141116</name>
      <address>
        <city>Tallinn</city>
        <state>Harjumaa</state>
        <zip>10128</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paernu Hospital /ID# 138961</name>
      <address>
        <city>Pärnu</city>
        <zip>80010</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Tallinn Central Hospital /ID# 140618</name>
      <address>
        <city>Tallinn</city>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki Univ Central Hospital /ID# 140381</name>
      <address>
        <city>Helsinki</city>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kiljava Medical Research /ID# 139260</name>
      <address>
        <city>Hyvinkaa</city>
        <zip>05800</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Karelia Central Hospital /ID# 139973</name>
      <address>
        <city>Lappeenranta</city>
        <zip>53130</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Joseph /ID# 149188</name>
      <address>
        <city>Marseille CEDEX 08</city>
        <state>Bouches-du-Rhone</state>
        <zip>13285</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Tours - Hopital Trousseau /ID# 138969</name>
      <address>
        <city>Chambray Les Tours</city>
        <zip>37170</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Koln /ID# 139084</name>
      <address>
        <city>Köln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Campus Mitte /ID# 139052</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Immanuel-Krankenhaus /ID# 139059</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Altona /ID# 140466</name>
      <address>
        <city>Hamburg</city>
        <zip>22763</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Welcker, Planegg, DE /ID# 140467</name>
      <address>
        <city>Planegg</city>
        <zip>82152</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Heraklion &quot;PA.G.N.I&quot; /ID# 139115</name>
      <address>
        <city>Heraklion</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital /ID# 139314</name>
      <address>
        <city>Sha Tin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revita Reumatologiai Rendelo /ID# 140761</name>
      <address>
        <city>Budapest</city>
        <zip>1027</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fejer Megyei Szent Gyorgy Korh /ID# 138554</name>
      <address>
        <city>Szekesfehervar</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's University Hosp /ID# 138562</name>
      <address>
        <city>Dublin</city>
        <zip>D04 T6F4</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita di Catanzaro Magna Graecia /ID# 139316</name>
      <address>
        <city>Catanzaro</city>
        <state>Calabria</state>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JSC Nat Scientific Med Res Ctr /ID# 140575</name>
      <address>
        <city>Astana</city>
        <zip>010009</zip>
        <country>Kazakhstan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital /ID# 149310</name>
      <address>
        <city>Incheon</city>
        <state>Gwang Yeogsi</state>
        <zip>22332</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital /ID# 149311</name>
      <address>
        <city>Suwon-si</city>
        <state>Gyeonggido</state>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital /ID# 138651</name>
      <address>
        <city>Gwangju</city>
        <state>Jeonranamdo</state>
        <zip>61469</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanyang University Seoul Hospi /ID# 138655</name>
      <address>
        <city>Seoul</city>
        <state>Seongdong-gu</state>
        <zip>04763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cath Univ Seoul St Mary's Hosp /ID# 138652</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic University Med /ID# 139249</name>
      <address>
        <city>Daegu</city>
        <zip>705-718</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital /ID# 138653</name>
      <address>
        <city>Daejeon</city>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital /ID# 138659</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center /ID# 140579</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LTD M+M Centers /ID# 138818</name>
      <address>
        <city>Adazi</city>
        <zip>2164</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klaipeda University Hospital /ID# 141416</name>
      <address>
        <city>Klaipeda</city>
        <zip>92288</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vilnius University Hospital /ID# 141348</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Peninsular de Investigación Clínica SCP /ID# 148160</name>
      <address>
        <city>Colonia Centro</city>
        <state>Yucatan</state>
        <zip>97000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad de Investigacion de las Enfermedades Reumatologicas SA de CV /ID# 138841</name>
      <address>
        <city>Mexico City</city>
        <zip>06090</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Porter Rheumatology Ltd /ID# 138347</name>
      <address>
        <city>Nelson</city>
        <zip>7010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Nasz Lekarz /ID# 138374</name>
      <address>
        <city>Toruń</city>
        <state>Kujawsko-pomorskie</state>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McBk Sc /Id# 138360</name>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <state>Mazowieckie</state>
        <zip>05-825</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osteo-Medic spolka cywilna /ID# 138371</name>
      <address>
        <city>Białystok</city>
        <state>Podlaskie</state>
        <zip>15-351</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Centrum Reumatologiczne /ID# 138353</name>
      <address>
        <city>Elblag</city>
        <state>Warminsko-mazurskie</state>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheuma Medicus /ID# 138372</name>
      <address>
        <city>Warsaw</city>
        <zip>02-118</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Portugues De Reumatologia /ID# 148315</name>
      <address>
        <city>Lisbon</city>
        <state>Lisboa</state>
        <zip>1050-034</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Lisboa Ocidental, EPE /ID# 140594</name>
      <address>
        <city>Lisbon</city>
        <state>Lisboa</state>
        <zip>1349-019</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>School of Medicine University of Puerto Rico-Medical Sciences Campus /ID# 139328</name>
      <address>
        <city>San Juan</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta /ID# 138407</name>
      <address>
        <city>Cluj</city>
        <zip>400006</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Municipal Ploiesti /ID# 138405</name>
      <address>
        <city>Ploiesti</city>
        <zip>100337</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Ur /ID# 138393</name>
      <address>
        <city>Sibiu</city>
        <zip>550245</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC Novaya Klinika /ID# 139269</name>
      <address>
        <city>Pyatigorsk</city>
        <state>Stavropol Skiy Kray</state>
        <zip>357500</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kazan State Medical University /ID# 138413</name>
      <address>
        <city>Kazan</city>
        <state>Tatarstan, Respublika</state>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republican Clin Hos n.a. Baran /ID# 139273</name>
      <address>
        <city>Petrozavodsk</city>
        <zip>185019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samara Regional Clinical Hosp /ID# 148642</name>
      <address>
        <city>Samara</city>
        <zip>443095</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulyanovsk Regional Clin Hosp /ID# 139279</name>
      <address>
        <city>Ulyanovsk</city>
        <zip>432018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Voronezh State Medical Univers /ID# 148431</name>
      <address>
        <city>Voronezh</city>
        <zip>394036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yaroslavi State Medical Univer /ID# 139908</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARTROMAC n.o. /ID# 138428</name>
      <address>
        <city>Kosice</city>
        <zip>040 11</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnica Kosice Saca, a.s. /ID# 138918</name>
      <address>
        <city>Kosice</city>
        <zip>040 15</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Slovak research center Team Member, Thermium s.r.o. /ID# 139924</name>
      <address>
        <city>Pieštany</city>
        <zip>921 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Narodny ustav reumatickych chorob Piestany /ID# 138427</name>
      <address>
        <city>Pieštany</city>
        <zip>921 12</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>REUMA-GLOBAL, s.r.o. /ID# 139912</name>
      <address>
        <city>Trnava</city>
        <zip>91701</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Augustine's Medical Centre /ID# 141352</name>
      <address>
        <city>Berea</city>
        <state>Kwazulu-Natal</state>
        <zip>NL 4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Clinical Research Tr /ID# 138945</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7405</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winelands Medical Research Ctr /ID# 138944</name>
      <address>
        <city>Stellenbosch</city>
        <state>Western Cape</state>
        <zip>7600</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional de Malaga /ID# 138975</name>
      <address>
        <city>Málaga</city>
        <state>Malaga</state>
        <zip>29009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Univ de Elche /ID# 138991</name>
      <address>
        <city>Elche</city>
        <zip>03202</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clin Univ San Carlos /ID# 138993</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp Nuestra Senora Esperanza /ID# 138997</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15705</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HFR Fribourg - Hopital Canton /ID# 139155</name>
      <address>
        <city>Fribourg</city>
        <zip>1708</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hosp /ID# 139232</name>
      <address>
        <city>Taichung City</city>
        <state>Taichung</state>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital /ID# 140868</name>
      <address>
        <city>Tainan City</city>
        <state>Tainan</state>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan Univ Hosp /ID# 141443</name>
      <address>
        <city>Taipei City</city>
        <state>Taipei</state>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 140869</name>
      <address>
        <city>Kaohsiung</city>
        <zip>80708</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Far Eastern Memorial Hospital /ID# 140871</name>
      <address>
        <city>New Taipei City</city>
        <zip>22060</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hosp /ID# 139234</name>
      <address>
        <city>Taipei City</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankara Numune Training and Res /ID# 139237</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC Revmocentr /ID# 139872</name>
      <address>
        <city>Kyiv</city>
        <zip>04070</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MNCE &quot;Lviv City Clinical Hospital #4&quot; /ID# 139873</name>
      <address>
        <city>Lviv</city>
        <zip>79007</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odessa National Medical Univ /ID# 139179</name>
      <address>
        <city>Odesa</city>
        <zip>65026</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary /ID# 139184</name>
      <address>
        <city>Leicester</city>
        <state>England</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Whipps Cross Univ Hospital /ID# 139523</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>E11 1NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Free Hospital /ID# 139191</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western General Hospital /ID# 139524</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital /ID# 139169</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warrington + Halton Hosp NHS /ID# 139195</name>
      <address>
        <city>Warrington</city>
        <zip>WA5 1LZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bosnia and Herzegovina</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Kazakhstan</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Belarus</country>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Serbia</country>
    <country>Singapore</country>
  </removed_countries>
  <link>
    <url>https://www.rxabbvie.com/</url>
    <description>Related Info.</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 11, 2015</study_first_submitted>
  <study_first_submitted_qc>February 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2016</study_first_posted>
  <results_first_submitted>September 13, 2019</results_first_submitted>
  <results_first_submitted_qc>September 13, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 7, 2019</results_first_posted>
  <disposition_first_submitted>January 9, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>January 15, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 17, 2018</disposition_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Musculoskeletal Disease</keyword>
  <keyword>Arthritis</keyword>
  <keyword>Joint Disease</keyword>
  <keyword>Anti-inflammatory agents</keyword>
  <keyword>Antirheumatic agents</keyword>
  <keyword>Upadacitinib</keyword>
  <keyword>ABT-494</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Upadacitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 26, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT02675426/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 14, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT02675426/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were randomized at 150 centers in 35 countries in North America, eastern and western Europe, Asia, South America, Australia, New Zealand, and South Africa.
The study had a 12-week placebo-controlled, double-blind period (Period 1), and an ongoing 5-year double-blind extension (Period 2). Results for Period 1 are reported.</recruitment_details>
      <pre_assignment_details>Participants were randomly assigned in a 1:1:1 ratio to 15 or 30 mg upadacitinib or placebo. Randomization was stratified by prior exposure to biologic disease-modifying anti-rheumatic drug (bDMARD) and geographical region. Participants assigned to placebo were switched to 15 or 30 mg upadacitinib at week 12 according to randomization assignment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants randomized to receive placebo once daily for 12 weeks in Period 1.</description>
        </group>
        <group group_id="P2">
          <title>Upadacitinib 15 mg</title>
          <description>Participants randomized to receive upadacitinib 15 mg once daily for 12 weeks in Period 1.</description>
        </group>
        <group group_id="P3">
          <title>Upadacitinib 30 mg</title>
          <description>Participants randomized to receive upadacitinib 30 mg once daily for 12 weeks in Period 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="221"/>
                <participants group_id="P2" count="221"/>
                <participants group_id="P3" count="219"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="221"/>
                <participants group_id="P2" count="221"/>
                <participants group_id="P3" count="219"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="208"/>
                <participants group_id="P2" count="213"/>
                <participants group_id="P3" count="201"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Full Analysis Set (FAS) includes all randomized participants who received at least one dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants randomized to receive placebo once daily for 12 weeks in Period 1.</description>
        </group>
        <group group_id="B2">
          <title>Upadacitinib 15 mg</title>
          <description>Participants randomized to receive upadacitinib 15 mg once daily for 12 weeks in Period 1.</description>
        </group>
        <group group_id="B3">
          <title>Upadacitinib 30 mg</title>
          <description>Participants randomized to receive upadacitinib 30 mg once daily for 12 weeks in Period 1.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="221"/>
            <count group_id="B2" value="221"/>
            <count group_id="B3" value="219"/>
            <count group_id="B4" value="661"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="221"/>
                    <count group_id="B2" value="221"/>
                    <count group_id="B3" value="219"/>
                    <count group_id="B4" value="661"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.0" spread="12.22"/>
                    <measurement group_id="B2" value="55.3" spread="11.47"/>
                    <measurement group_id="B3" value="55.8" spread="11.29"/>
                    <measurement group_id="B4" value="55.7" spread="11.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="221"/>
                    <count group_id="B2" value="221"/>
                    <count group_id="B3" value="219"/>
                    <count group_id="B4" value="661"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt; 40 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>40 to 64 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="145"/>
                    <measurement group_id="B2" value="153"/>
                    <measurement group_id="B3" value="145"/>
                    <measurement group_id="B4" value="443"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="221"/>
                    <count group_id="B2" value="221"/>
                    <count group_id="B3" value="219"/>
                    <count group_id="B4" value="661"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="166"/>
                    <measurement group_id="B2" value="182"/>
                    <measurement group_id="B3" value="172"/>
                    <measurement group_id="B4" value="520"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="221"/>
                    <count group_id="B2" value="221"/>
                    <count group_id="B3" value="219"/>
                    <count group_id="B4" value="661"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="194"/>
                    <measurement group_id="B2" value="198"/>
                    <measurement group_id="B3" value="189"/>
                    <measurement group_id="B4" value="581"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="221"/>
                    <count group_id="B2" value="221"/>
                    <count group_id="B3" value="219"/>
                    <count group_id="B4" value="661"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="187"/>
                    <measurement group_id="B2" value="188"/>
                    <measurement group_id="B3" value="186"/>
                    <measurement group_id="B4" value="561"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian / Alaskan Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Multiple</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Geographical Region</title>
          <description>Other includes Australia, New Zealand, and South Africa.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="221"/>
                    <count group_id="B2" value="221"/>
                    <count group_id="B3" value="219"/>
                    <count group_id="B4" value="661"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>North America</title>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="89"/>
                    <measurement group_id="B4" value="267"/>
                  </measurement_list>
                </category>
                <category>
                  <title>South/Central America</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Western Europe</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Eastern Europe</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="73"/>
                    <measurement group_id="B4" value="223"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asia</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Biological DMARD Use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="221"/>
                    <count group_id="B2" value="221"/>
                    <count group_id="B3" value="219"/>
                    <count group_id="B4" value="661"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="192"/>
                    <measurement group_id="B2" value="194"/>
                    <measurement group_id="B3" value="191"/>
                    <measurement group_id="B4" value="577"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Rheumatoid Arthritis (RA) Diagnosis</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="221"/>
                    <count group_id="B2" value="221"/>
                    <count group_id="B3" value="219"/>
                    <count group_id="B4" value="661"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.2" spread="7.45"/>
                    <measurement group_id="B2" value="7.3" spread="7.89"/>
                    <measurement group_id="B3" value="7.3" spread="7.86"/>
                    <measurement group_id="B4" value="7.3" spread="7.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Conventional Synthetic DMARD (csDMARD) Use at Baseline</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="221"/>
                    <count group_id="B2" value="221"/>
                    <count group_id="B3" value="219"/>
                    <count group_id="B4" value="661"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Methotrexate alone</title>
                  <measurement_list>
                    <measurement group_id="B1" value="141"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="136"/>
                    <measurement group_id="B4" value="399"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Methotrexate and other csDMARD</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="135"/>
                  </measurement_list>
                </category>
                <category>
                  <title>csDMARD other than methotrexate</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="125"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tender Joint Count</title>
          <description>A total of 68 joints were assessed for the presence or absence of tenderness.</description>
          <units>tender joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="221"/>
                    <count group_id="B2" value="221"/>
                    <count group_id="B3" value="219"/>
                    <count group_id="B4" value="661"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.7" spread="14.96"/>
                    <measurement group_id="B2" value="25.2" spread="13.80"/>
                    <measurement group_id="B3" value="26.2" spread="14.26"/>
                    <measurement group_id="B4" value="25.4" spread="14.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Swollen Joint Count</title>
          <description>A total of 66 joints were assessed for the presence or absence of swelling.</description>
          <units>swollen joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="221"/>
                    <count group_id="B2" value="221"/>
                    <count group_id="B3" value="219"/>
                    <count group_id="B4" value="661"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.4" spread="9.24"/>
                    <measurement group_id="B2" value="16.0" spread="10.04"/>
                    <measurement group_id="B3" value="16.2" spread="10.55"/>
                    <measurement group_id="B4" value="15.8" spread="9.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient's Assessment of Pain</title>
          <description>Participants were asked to indicate the severity of their arthritis pain within the previous week on a visual analog scale (VAS) from 0 to 100. A score of 0 indicates &quot;no pain&quot; and a score of 100 indicates &quot;worst possible pain.&quot;</description>
          <population>Participants with available data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="221"/>
                    <count group_id="B2" value="217"/>
                    <count group_id="B3" value="219"/>
                    <count group_id="B4" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.5" spread="20.80"/>
                    <measurement group_id="B2" value="64.1" spread="19.45"/>
                    <measurement group_id="B3" value="64.0" spread="19.77"/>
                    <measurement group_id="B4" value="63.2" spread="20.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient’s Global Assessment of Disease Activity</title>
          <description>The participant was asked to rate their current RA disease activity over the past 24 hours ranging from 0 to 100 using a VAS, where 0 indicates very low disease activity and 100 indicates very high disease activity.</description>
          <population>Participants with available data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="221"/>
                    <count group_id="B2" value="217"/>
                    <count group_id="B3" value="219"/>
                    <count group_id="B4" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.3" spread="20.50"/>
                    <measurement group_id="B2" value="63.1" spread="21.86"/>
                    <measurement group_id="B3" value="62.8" spread="20.32"/>
                    <measurement group_id="B4" value="62.1" spread="20.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Physician's Global Assessment of Disease Activity</title>
          <description>The physician rated the participant's current global RA disease activity (independently from the participant's assessment) on a VAS scale from 0 to 100, where 0 indicates very low disease activity and 100 indicates very high disease activity.</description>
          <population>Participants with available data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="211"/>
                    <count group_id="B2" value="209"/>
                    <count group_id="B3" value="213"/>
                    <count group_id="B4" value="633"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.4" spread="17.67"/>
                    <measurement group_id="B2" value="64.3" spread="16.22"/>
                    <measurement group_id="B3" value="63.0" spread="17.99"/>
                    <measurement group_id="B4" value="63.9" spread="17.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Health Assessment Questionnaire – Disability Index (HAQ-DI)</title>
          <description>The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability.</description>
          <population>Participants with available data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="221"/>
                    <count group_id="B2" value="216"/>
                    <count group_id="B3" value="219"/>
                    <count group_id="B4" value="656"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.4" spread="0.63"/>
                    <measurement group_id="B2" value="1.5" spread="0.61"/>
                    <measurement group_id="B3" value="1.5" spread="0.61"/>
                    <measurement group_id="B4" value="1.5" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High-sensitivity C-reactive Protein (hsCRP)</title>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="221"/>
                    <count group_id="B2" value="221"/>
                    <count group_id="B3" value="219"/>
                    <count group_id="B4" value="661"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.6" spread="13.96"/>
                    <measurement group_id="B2" value="16.6" spread="19.17"/>
                    <measurement group_id="B3" value="14.8" spread="16.86"/>
                    <measurement group_id="B4" value="14.7" spread="16.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease Activity Score Based on CRP (DAS28 [CRP])</title>
          <description>The DAS28 (CRP) is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28 score &gt; 5.1 indicates high disease activity, a DAS28 score ≤ 3.2 indicates low disease activity, and a DAS28 score &lt; 2.6 indicates clinical remission.</description>
          <population>Participants with available data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="221"/>
                    <count group_id="B2" value="217"/>
                    <count group_id="B3" value="219"/>
                    <count group_id="B4" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.6" spread="0.84"/>
                    <measurement group_id="B2" value="5.7" spread="0.97"/>
                    <measurement group_id="B3" value="5.7" spread="0.90"/>
                    <measurement group_id="B4" value="5.6" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12</title>
        <description>The primary endpoint for United States (US)/Food and Drug Administration (FDA) regulatory purposes was ACR 20% response (ACR20) at Week 12. Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria:
≥ 20% improvement in 68-tender joint count;
≥ 20% improvement in 66-swollen joint count; and
≥ 20% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Health Assessment Questionnaire - Disability Index (HAQ-DI)
High-sensitivity C-reactive protein (hsCRP).</description>
        <time_frame>Baseline and week 12</time_frame>
        <population>Full analysis set; participants who prematurely discontinued from study drug prior to week 12 or for whom ACR data were missing at week 12 were considered non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants randomized to receive placebo once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Upadacitinib 15 mg</title>
            <description>Participants randomized to receive upadacitinib 15 mg once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Upadacitinib 30 mg</title>
            <description>Participants randomized to receive upadacitinib 30 mg once daily for 12 weeks in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12</title>
          <description>The primary endpoint for United States (US)/Food and Drug Administration (FDA) regulatory purposes was ACR 20% response (ACR20) at Week 12. Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria:
≥ 20% improvement in 68-tender joint count;
≥ 20% improvement in 66-swollen joint count; and
≥ 20% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Health Assessment Questionnaire - Disability Index (HAQ-DI)
High-sensitivity C-reactive protein (hsCRP).</description>
          <population>Full analysis set; participants who prematurely discontinued from study drug prior to week 12 or for whom ACR data were missing at week 12 were considered non-responders.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="221"/>
                <count group_id="O3" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.7" lower_limit="29.4" upper_limit="42.1"/>
                    <measurement group_id="O2" value="63.8" lower_limit="57.5" upper_limit="70.1"/>
                    <measurement group_id="O3" value="66.2" lower_limit="59.9" upper_limit="72.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The overall type I error rate of the primary and ranked key secondary endpoints for the two doses was controlled using a graphical multiple testing procedure.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for the stratification factor of prior biological disease-modifying anti-rheumatoid drug use.</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>28.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>19.1</ci_lower_limit>
            <ci_upper_limit>37.0</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib – Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The overall type I error rate of the primary and ranked key secondary endpoints for the two doses was controlled using a graphical multiple testing procedure.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for the stratification factor of prior biological disease-modifying anti-rheumatoid drug use.</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>30.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>21.6</ci_lower_limit>
            <ci_upper_limit>39.4</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib – Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12</title>
        <description>The primary endpoint for European Union (EU)/European Medicines Agency (EMA) regulatory purposes was low disease activity, based on a Disease Activity Score 28 (DAS28)-CRP score of ≤ 3.2 at week 12.
The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.
A DAS28 score less than or equal to 3.2 indicates low disease activity.</description>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set; participants who prematurely discontinued from study drug prior to week 12 or for whom DAS28 data were missing at week 12 were considered non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants randomized to receive placebo once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Upadacitinib 15 mg</title>
            <description>Participants randomized to receive upadacitinib 15 mg once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Upadacitinib 30 mg</title>
            <description>Participants randomized to receive upadacitinib 30 mg once daily for 12 weeks in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12</title>
          <description>The primary endpoint for European Union (EU)/European Medicines Agency (EMA) regulatory purposes was low disease activity, based on a Disease Activity Score 28 (DAS28)-CRP score of ≤ 3.2 at week 12.
The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.
A DAS28 score less than or equal to 3.2 indicates low disease activity.</description>
          <population>Full analysis set; participants who prematurely discontinued from study drug prior to week 12 or for whom DAS28 data were missing at week 12 were considered non-responders.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="221"/>
                <count group_id="O3" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2" lower_limit="12.2" upper_limit="22.2"/>
                    <measurement group_id="O2" value="48.4" lower_limit="41.8" upper_limit="55.0"/>
                    <measurement group_id="O3" value="47.9" lower_limit="41.3" upper_limit="54.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The overall type I error rate of the primary and ranked key secondary endpoints for the two doses was controlled using a graphical multiple testing procedure.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for the stratification factor of prior biological disease-modifying anti-rheumatoid drug use.</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>31.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>23.0</ci_lower_limit>
            <ci_upper_limit>39.5</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib – Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The overall type I error rate of the primary and ranked key secondary endpoints for the two doses was controlled using a graphical multiple testing procedure.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for the stratification factor of prior biological disease-modifying anti-rheumatoid drug use.</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>30.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>22.5</ci_lower_limit>
            <ci_upper_limit>39.0</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in in Disease Activity Score 28 (CRP) at Week 12</title>
        <description>The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from baseline in DAS28 (CRP) indicates improvement in disease activity.</description>
        <time_frame>Baseline and week 12</time_frame>
        <population>Full analysis set participants with available data at baseline; multiple imputation was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants randomized to receive placebo once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Upadacitinib 15 mg</title>
            <description>Participants randomized to receive upadacitinib 15 mg once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Upadacitinib 30 mg</title>
            <description>Participants randomized to receive upadacitinib 30 mg once daily for 12 weeks in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in in Disease Activity Score 28 (CRP) at Week 12</title>
          <description>The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from baseline in DAS28 (CRP) indicates improvement in disease activity.</description>
          <population>Full analysis set participants with available data at baseline; multiple imputation was used for missing data.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="217"/>
                <count group_id="O3" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.02" lower_limit="-1.22" upper_limit="-0.82"/>
                    <measurement group_id="O2" value="-2.20" lower_limit="-2.40" upper_limit="-2.00"/>
                    <measurement group_id="O3" value="-2.34" lower_limit="-2.54" upper_limit="-2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The overall type I error rate of the primary and ranked key secondary endpoints for the two doses was controlled using a graphical multiple testing procedure.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment, prior bDMARD use and baseline value as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.42</ci_lower_limit>
            <ci_upper_limit>-0.94</ci_upper_limit>
            <estimate_desc>Treatment Difference = Upadacitinib – Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The overall type I error rate of the primary and ranked key secondary endpoints for the two doses was controlled using a graphical multiple testing procedure.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment, prior bDMARD use and baseline value as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.56</ci_lower_limit>
            <ci_upper_limit>-1.08</ci_upper_limit>
            <estimate_desc>Treatment Difference = Upadacitinib – Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12</title>
        <description>The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability.
A negative change from Baseline in the overall score indicates improvement.</description>
        <time_frame>Baseline and week 12</time_frame>
        <population>Full analysis set participants with available data at baseline; multiple imputation was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants randomized to receive placebo once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Upadacitinib 15 mg</title>
            <description>Participants randomized to receive upadacitinib 15 mg once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Upadacitinib 30 mg</title>
            <description>Participants randomized to receive upadacitinib 30 mg once daily for 12 weeks in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12</title>
          <description>The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability.
A negative change from Baseline in the overall score indicates improvement.</description>
          <population>Full analysis set participants with available data at baseline; multiple imputation was used for missing data.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="216"/>
                <count group_id="O3" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" lower_limit="-0.34" upper_limit="-0.17"/>
                    <measurement group_id="O2" value="-0.59" lower_limit="-0.67" upper_limit="-0.51"/>
                    <measurement group_id="O3" value="-0.54" lower_limit="-0.62" upper_limit="-0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The overall type I error rate of the primary and ranked key secondary endpoints for the two doses was controlled using a graphical multiple testing procedure.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment, prior bDMARD use and baseline value as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.43</ci_lower_limit>
            <ci_upper_limit>-0.24</ci_upper_limit>
            <estimate_desc>Treatment Difference = Upadacitinib – Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The overall type I error rate of the primary and ranked key secondary endpoints for the two doses was controlled using a graphical multiple testing procedure.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment, prior bDMARD use and baseline value as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.38</ci_lower_limit>
            <ci_upper_limit>-0.18</ci_upper_limit>
            <estimate_desc>Treatment Difference = Upadacitinib – Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12</title>
        <description>The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health).
The physical component score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from baseline score indicates an improvement.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set participants with available data; a mixed effect model repeat measurement (MMRM) analysis with data from observed cases to week 12 was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants randomized to receive placebo once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Upadacitinib 15 mg</title>
            <description>Participants randomized to receive upadacitinib 15 mg once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Upadacitinib 30 mg</title>
            <description>Participants randomized to receive upadacitinib 30 mg once daily for 12 weeks in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12</title>
          <description>The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health).
The physical component score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from baseline score indicates an improvement.</description>
          <population>Full analysis set participants with available data; a mixed effect model repeat measurement (MMRM) analysis with data from observed cases to week 12 was used.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="209"/>
                <count group_id="O3" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.03" lower_limit="1.88" upper_limit="4.18"/>
                    <measurement group_id="O2" value="7.58" lower_limit="6.43" upper_limit="8.74"/>
                    <measurement group_id="O3" value="8.01" lower_limit="6.84" upper_limit="9.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The overall type I error rate of the primary and ranked key secondary endpoints for the two doses was controlled using a graphical multiple testing procedure.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.</p_value_desc>
            <method>Mixed Effect Model Repeat Measurement</method>
            <method_desc>MMRM model with fixed effects of treatment, visit, and treatment-by-visit interaction, previous bDMARD use, and baseline value as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>4.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.13</ci_lower_limit>
            <ci_upper_limit>5.98</ci_upper_limit>
            <estimate_desc>Treatment Difference = Upadacitinib – Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The overall type I error rate of the primary and ranked key secondary endpoints for the two doses was controlled using a graphical multiple testing procedure.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.</p_value_desc>
            <method>Mixed Effect Model Repeat Measurement</method>
            <method_desc>MMRM model with fixed effects of treatment, visit, and treatment-by-visit interaction, previous bDMARD use, and baseline value as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>4.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.54</ci_lower_limit>
            <ci_upper_limit>6.42</ci_upper_limit>
            <estimate_desc>Treatment Difference = Upadacitinib – Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Clinical Remission Based on DAS28 (CRP) at Week 12</title>
        <description>Clinical remission (CR) based on DAS28 (CRP) is defined as achieving a DAS28 (CRP) of less than 2.6.
DAS28 (CRP) is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.</description>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set; participants who prematurely discontinued from study drug prior to week 12 or for whom DAS28 (CRP) data were missing at week 12 were considered non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants randomized to receive placebo once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Upadacitinib 15 mg</title>
            <description>Participants randomized to receive upadacitinib 15 mg once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Upadacitinib 30 mg</title>
            <description>Participants randomized to receive upadacitinib 30 mg once daily for 12 weeks in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Clinical Remission Based on DAS28 (CRP) at Week 12</title>
          <description>Clinical remission (CR) based on DAS28 (CRP) is defined as achieving a DAS28 (CRP) of less than 2.6.
DAS28 (CRP) is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.</description>
          <population>Full analysis set; participants who prematurely discontinued from study drug prior to week 12 or for whom DAS28 (CRP) data were missing at week 12 were considered non-responders.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="221"/>
                <count group_id="O3" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="6.0" upper_limit="13.9"/>
                    <measurement group_id="O2" value="30.8" lower_limit="24.7" upper_limit="36.9"/>
                    <measurement group_id="O3" value="28.3" lower_limit="22.3" upper_limit="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The overall type I error rate of the primary and ranked key secondary endpoints for the two doses was controlled using a graphical multiple testing procedure.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for the stratification factor of prior biological disease-modifying anti-rheumatoid drug use.</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>20.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.6</ci_lower_limit>
            <ci_upper_limit>28.1</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The overall type I error rate of the primary and ranked key secondary endpoints for the two doses was controlled using a graphical multiple testing procedure.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for the stratification factor of prior biological disease-modifying anti-rheumatoid drug use.</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>18.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.2</ci_lower_limit>
            <ci_upper_limit>25.5</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Low Disease Activity Based on CDAI at Week 12</title>
        <description>Low disease activity based on the clinical disease activity index (CDAI) is defined as a CDAI score ≤ 10.
CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity.</description>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set; participants who prematurely discontinued from study drug prior to week 12 or for whom CDAI data were missing at week 12 were considered non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants randomized to receive placebo once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Upadacitinib 15 mg</title>
            <description>Participants randomized to receive upadacitinib 15 mg once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Upadacitinib 30 mg</title>
            <description>Participants randomized to receive upadacitinib 30 mg once daily for 12 weeks in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Low Disease Activity Based on CDAI at Week 12</title>
          <description>Low disease activity based on the clinical disease activity index (CDAI) is defined as a CDAI score ≤ 10.
CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity.</description>
          <population>Full analysis set; participants who prematurely discontinued from study drug prior to week 12 or for whom CDAI data were missing at week 12 were considered non-responders.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="221"/>
                <count group_id="O3" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" lower_limit="13.8" upper_limit="24.2"/>
                    <measurement group_id="O2" value="40.3" lower_limit="33.8" upper_limit="46.7"/>
                    <measurement group_id="O3" value="42.0" lower_limit="35.5" upper_limit="48.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The overall type I error rate of the primary and ranked key secondary endpoints for the two doses was controlled using a graphical multiple testing procedure.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for the stratification factor of prior biological disease-modifying anti-rheumatoid drug use.</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>21.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.0</ci_lower_limit>
            <ci_upper_limit>29.5</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The overall type I error rate of the primary and ranked key secondary endpoints for the two doses was controlled using a graphical multiple testing procedure.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for the stratification factor of prior biological disease-modifying anti-rheumatoid drug use.</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>23.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>14.7</ci_lower_limit>
            <ci_upper_limit>31.3</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Duration of Morning Stiffness at Week 12</title>
        <description>Participants were asked to indicate the time it took for them to get as limber as possible after awakening with morning stiffness over the past 7 days.</description>
        <time_frame>Baseline and week 12</time_frame>
        <population>Full analysis set participants with available data; a mixed effect model repeat measurement (MMRM) analysis with data from observed cases to week 12 was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants randomized to receive placebo once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Upadacitinib 15 mg</title>
            <description>Participants randomized to receive upadacitinib 15 mg once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Upadacitinib 30 mg</title>
            <description>Participants randomized to receive upadacitinib 30 mg once daily for 12 weeks in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Duration of Morning Stiffness at Week 12</title>
          <description>Participants were asked to indicate the time it took for them to get as limber as possible after awakening with morning stiffness over the past 7 days.</description>
          <population>Full analysis set participants with available data; a mixed effect model repeat measurement (MMRM) analysis with data from observed cases to week 12 was used.</population>
          <units>minutes</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.27" lower_limit="-54.63" upper_limit="-13.91"/>
                    <measurement group_id="O2" value="-85.28" lower_limit="-105.61" upper_limit="-64.95"/>
                    <measurement group_id="O3" value="-85.13" lower_limit="-105.65" upper_limit="-64.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The overall type I error rate of the primary and ranked key secondary endpoints for the two doses was controlled using a graphical multiple testing procedure.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.</p_value_desc>
            <method>Mixed Effect Model Repeat Measurement</method>
            <method_desc>MMRM model with fixed effects of treatment, visit, and treatment-by-visit interaction, previous bDMARD use, and baseline value as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-51.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-78.14</ci_lower_limit>
            <ci_upper_limit>-23.87</ci_upper_limit>
            <estimate_desc>Treatment Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The overall type I error rate of the primary and ranked key secondary endpoints for the two doses was controlled using a graphical multiple testing procedure.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.</p_value_desc>
            <method>Mixed Effect Model Repeat Measurement</method>
            <method_desc>MMRM model with fixed effects of treatment, visit, and treatment-by-visit interaction, previous bDMARD use, and baseline value as covariate.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-50.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-78.19</ci_lower_limit>
            <ci_upper_limit>-23.53</ci_upper_limit>
            <estimate_desc>Treatment Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F)</title>
        <description>The FACIT Fatigue scale is a 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four point Likert scale. The FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from baseline indicates improvement.</description>
        <time_frame>Baseline and week 12</time_frame>
        <population>Full analysis set participants with available data; a mixed effect model repeat measurement (MMRM) analysis with data from observed cases to week 12 was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants randomized to receive placebo once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Upadacitinib 15 mg</title>
            <description>Participants randomized to receive upadacitinib 15 mg once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Upadacitinib 30 mg</title>
            <description>Participants randomized to receive upadacitinib 30 mg once daily for 12 weeks in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F)</title>
          <description>The FACIT Fatigue scale is a 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four point Likert scale. The FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from baseline indicates improvement.</description>
          <population>Full analysis set participants with available data; a mixed effect model repeat measurement (MMRM) analysis with data from observed cases to week 12 was used.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.96" lower_limit="1.62" upper_limit="4.30"/>
                    <measurement group_id="O2" value="7.91" lower_limit="6.56" upper_limit="9.27"/>
                    <measurement group_id="O3" value="7.74" lower_limit="6.38" upper_limit="9.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The overall type I error rate of the primary and ranked key secondary endpoints for the two doses was controlled using a graphical multiple testing procedure.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.</p_value_desc>
            <method>Mixed Effect Model Repeat Measurement</method>
            <method_desc>MMRM model with fixed effects of treatment, visit, and treatment-by-visit interaction, previous bDMARD use, and baseline value as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>4.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.31</ci_lower_limit>
            <ci_upper_limit>6.60</ci_upper_limit>
            <estimate_desc>Treatment Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The overall type I error rate of the primary and ranked key secondary endpoints for the two doses was controlled using a graphical multiple testing procedure.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.</p_value_desc>
            <method>Mixed Effect Model Repeat Measurement</method>
            <method_desc>MMRM model with fixed effects of treatment, visit, and treatment-by-visit interaction, previous bDMARD use, and baseline value as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>4.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.12</ci_lower_limit>
            <ci_upper_limit>6.44</ci_upper_limit>
            <estimate_desc>Treatment Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12</title>
        <description>Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR50 response criteria:
≥ 50% improvement in 68-tender joint count;
≥ 50% improvement in 66-swollen joint count; and
≥ 50% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Health Assessment Questionnaire - Disability Index (HAQ-DI)
High-sensitivity C-reactive protein (hsCRP).</description>
        <time_frame>Baseline and week 12</time_frame>
        <population>Full analysis set; participants who prematurely discontinued from study drug prior to week 12 or for whom ACR data were missing at week 12 were considered non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants randomized to receive placebo once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Upadacitinib 15 mg</title>
            <description>Participants randomized to receive upadacitinib 15 mg once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Upadacitinib 30 mg</title>
            <description>Participants randomized to receive upadacitinib 30 mg once daily for 12 weeks in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12</title>
          <description>Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR50 response criteria:
≥ 50% improvement in 68-tender joint count;
≥ 50% improvement in 66-swollen joint count; and
≥ 50% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Health Assessment Questionnaire - Disability Index (HAQ-DI)
High-sensitivity C-reactive protein (hsCRP).</description>
          <population>Full analysis set; participants who prematurely discontinued from study drug prior to week 12 or for whom ACR data were missing at week 12 were considered non-responders.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="221"/>
                <count group_id="O3" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" lower_limit="10.2" upper_limit="19.6"/>
                    <measurement group_id="O2" value="38.0" lower_limit="31.6" upper_limit="44.4"/>
                    <measurement group_id="O3" value="43.4" lower_limit="36.8" upper_limit="49.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Unadjusted p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for the stratification factor of prior biological disease-modifying anti-rheumatoid drug use.</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>23.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>15.1</ci_lower_limit>
            <ci_upper_limit>31.0</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Unadjusted p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for the stratification factor of prior biological disease-modifying anti-rheumatoid drug use.</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>28.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>20.4</ci_lower_limit>
            <ci_upper_limit>36.5</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12</title>
        <description>Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR70 response criteria:
≥ 70% improvement in 68-tender joint count;
≥ 70% improvement in 66-swollen joint count; and
≥ 70% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Health Assessment Questionnaire - Disability Index (HAQ-DI)
High-sensitivity C-reactive protein (hsCRP).</description>
        <time_frame>Baseline and week 12</time_frame>
        <population>Full analysis set; participants who prematurely discontinued from study drug prior to week 12 or for whom ACR data were missing at week 12 were considered non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants randomized to receive placebo once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Upadacitinib 15 mg</title>
            <description>Participants randomized to receive upadacitinib 15 mg once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Upadacitinib 30 mg</title>
            <description>Participants randomized to receive upadacitinib 30 mg once daily for 12 weeks in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12</title>
          <description>Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR70 response criteria:
≥ 70% improvement in 68-tender joint count;
≥ 70% improvement in 66-swollen joint count; and
≥ 70% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Health Assessment Questionnaire - Disability Index (HAQ-DI)
High-sensitivity C-reactive protein (hsCRP).</description>
          <population>Full analysis set; participants who prematurely discontinued from study drug prior to week 12 or for whom ACR data were missing at week 12 were considered non-responders.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="221"/>
                <count group_id="O3" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" lower_limit="2.8" upper_limit="9.0"/>
                    <measurement group_id="O2" value="20.8" lower_limit="15.5" upper_limit="26.2"/>
                    <measurement group_id="O3" value="26.5" lower_limit="20.6" upper_limit="32.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Unadjusted p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for the stratification factor of prior biological disease-modifying anti-rheumatoid drug use.</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>14.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.7</ci_lower_limit>
            <ci_upper_limit>21.1</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Unadjusted p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for the stratification factor of prior biological disease-modifying anti-rheumatoid drug use.</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>20.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>14.0</ci_lower_limit>
            <ci_upper_limit>27.2</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1</title>
        <description>Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria:
≥ 20% improvement in 68-tender joint count;
≥ 20% improvement in 66-swollen joint count; and
≥ 20% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Health Assessment Questionnaire - Disability Index (HAQ-DI)
High-sensitivity C-reactive protein (hsCRP).</description>
        <time_frame>Baseline and week 1</time_frame>
        <population>Full analysis set; participants who prematurely discontinued from study drug prior to week 1 or for whom ACR data were missing at week 1 were considered non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants randomized to receive placebo once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Upadacitinib 15 mg</title>
            <description>Participants randomized to receive upadacitinib 15 mg once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Upadacitinib 30 mg</title>
            <description>Participants randomized to receive upadacitinib 30 mg once daily for 12 weeks in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1</title>
          <description>Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria:
≥ 20% improvement in 68-tender joint count;
≥ 20% improvement in 66-swollen joint count; and
≥ 20% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Health Assessment Questionnaire - Disability Index (HAQ-DI)
High-sensitivity C-reactive protein (hsCRP).</description>
          <population>Full analysis set; participants who prematurely discontinued from study drug prior to week 1 or for whom ACR data were missing at week 1 were considered non-responders.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="221"/>
                <count group_id="O3" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" lower_limit="4.9" upper_limit="12.3"/>
                    <measurement group_id="O2" value="22.2" lower_limit="16.7" upper_limit="27.6"/>
                    <measurement group_id="O3" value="28.3" lower_limit="22.3" upper_limit="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Unadjusted p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for the stratification factor of prior biological disease-modifying anti-rheumatoid drug use.</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>13.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.0</ci_lower_limit>
            <ci_upper_limit>20.2</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Unadjusted p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for the stratification factor of prior biological disease-modifying anti-rheumatoid drug use</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>19.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.7</ci_lower_limit>
            <ci_upper_limit>26.7</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first dose of study drug up to week 12 or up to 30 days after last dose for participants who discontinued study drug prior to week 12.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received placebo once daily for 12 weeks in Period 1.</description>
        </group>
        <group group_id="E2">
          <title>Upadacitinib 15 mg</title>
          <description>Participants received upadacitinib 15 mg once daily for 12 weeks in Period 1.</description>
        </group>
        <group group_id="E3">
          <title>Upadacitinib 30 mg</title>
          <description>Participants received upadacitinib 30 mg once daily for 12 weeks in Period 1.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>LYMPHADENITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ENTEROCOLITIS INFECTIOUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>VARICELLA ZOSTER VIRUS INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>VIRAL UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION STAPHYLOCOCCAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>SPINAL COMPRESSION FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>WRIST FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>B-CELL SMALL LYMPHOCYTIC LYMPHOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>CHRONIC LYMPHOCYTIC LEUKAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>OVARIAN GERM CELL TERATOMA BENIGN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>ISCHAEMIC STROKE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>SUICIDE ATTEMPT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>OVARIAN CYST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ORGANISING PNEUMONIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="221"/>
                <counts group_id="E2" events="19" subjects_affected="16" subjects_at_risk="221"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="221"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="221"/>
                <counts group_id="E3" events="14" subjects_affected="13" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="221"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="221"/>
                <counts group_id="E3" events="13" subjects_affected="12" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="221"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="221"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>AbbVie</organization>
      <phone>800-633-9110</phone>
      <email>abbvieclinicaltrials@abbvie.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

